Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

BACKGROUND: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has proven to prolong progression-free survival (PFS) in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). Few data are available regar...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ther Adv Med Oncol
Glavni autori: Palumbo, Raffaella, Torrisi, Rosalba, Sottotetti, Federico, Presti, Daniele, Rita Gambaro, Anna, Collovà, Elena, Ferzi, Antonella, Agostinetto, Elisa, Maria Teragni, Cristina, Saltalamacchia, Giuseppe, Tagliaferri, Barbara, Balletti, Emanuela, Bernardo, Antonio, Quaquarini, Erica
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2021
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970542/
https://ncbi.nlm.nih.gov/pubmed/33796150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920987651
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items